Overview
Structural abnormalities of the subarachnoid space (SAS), particularly an enlarged extra-axial cerebrospinal fluid (eaCSF) volume, represent a notable finding in pediatric neuroimaging. These abnormalities can manifest as increased fluid accumulation outside the brain parenchyma but within the subarachnoid space. Early detection and understanding of these anomalies are crucial due to their potential associations with neurodevelopmental outcomes, such as autism spectrum disorder (ASD) and cognitive function. The variability in presentation, from asymptomatic cases to those with rapid head growth, underscores the complexity of managing these conditions. This guideline aims to provide clinicians with a comprehensive understanding of the pathophysiology, epidemiology, clinical presentation, diagnosis, differential diagnosis, prognosis, follow-up considerations, and special population insights related to SAS abnormalities.
Pathophysiology
The pathophysiology of structural abnormalities in the subarachnoid space is multifaceted and involves dynamic changes in cerebrospinal fluid (CSF) dynamics and brain growth patterns. MRI-derived growth charts reveal that extra-axial cerebrospinal fluid (eaCSF) volume declines sharply during infancy, reflecting the rapid brain growth and compaction that occurs in early childhood [PMID:41369522]. Typically, this volume stabilizes around the first year of life and then gradually increases around 6 years of age, highlighting the importance of age-specific reference trajectories for accurate interpretation. These developmental changes suggest that deviations from normative patterns could indicate underlying pathologies affecting CSF dynamics or brain development. The mechanisms underlying these abnormalities may include genetic predispositions, disruptions in CSF absorption, or impaired brain-CSF interactions, though specific causal factors remain areas of ongoing research.
Epidemiology
Structural abnormalities of the subarachnoid space, characterized by increased eaCSF volumes, have been observed in various clinical contexts, with notable associations emerging in pediatric populations. Studies indicate that infants exhibiting elevated eaCSF volumes as early as 6 months of age are at a higher risk of later diagnoses of autism spectrum disorder (ASD) [PMID:41369522]. These elevated volumes tend to persist until approximately 3 years of age, suggesting a prolonged period of potential neurodevelopmental impact. Additionally, the prevalence of these abnormalities may vary, influenced by factors such as genetic predispositions and familial histories. For instance, cases reported in the literature highlight instances where infants with rapid head circumference growth and family histories of macrocephaly showed normal neurodevelopmental outcomes, indicating that increased eaCSF alone does not definitively predict adverse outcomes [PMID:12653385]. Understanding these epidemiological trends is crucial for early identification and targeted monitoring in high-risk populations.
Clinical Presentation
The clinical presentation of structural abnormalities in the subarachnoid space can vary widely, ranging from asymptomatic states to more overt symptoms. Increased eaCSF volumes have been correlated with specific neurodevelopmental concerns, particularly in pediatric patients. Lower verbal abilities and increased sleep disturbances are notable manifestations observed in these populations [PMID:41369522]. These cognitive and behavioral symptoms may reflect underlying disruptions in brain development or function influenced by altered CSF dynamics. Clinically, two illustrative cases presented with rapid increases in head circumference, a hallmark sign often associated with conditions like benign enlargement of the subarachnoid space (BESS). Despite these physical findings, both infants demonstrated normal neurodevelopmental assessments, underscoring the complexity in linking imaging findings directly to functional outcomes [PMID:12653385]. This variability emphasizes the need for comprehensive clinical evaluations that integrate neuroimaging data with developmental assessments.
Diagnosis
Diagnosing structural abnormalities of the subarachnoid space relies heavily on advanced neuroimaging techniques, particularly MRI, which offers high-resolution images necessary for accurate measurement and interpretation. An automated computational pipeline applied to clinical MRI scans has shown promise in effectively measuring eaCSF thickness, distinguishing patients with benign enlargement of the subarachnoid space (BESS) from controls using standardized growth charts [PMID:41369522]. Radiologic findings in reported cases often reveal fluid collections within the subarachnoid space without concurrent changes in ventricular size, which is crucial for differentiating BESS from other conditions like hydrocephalus. This distinction is pivotal for appropriate management and prognosis. Clinicians should be vigilant in correlating imaging findings with clinical symptoms and developmental milestones to ensure a comprehensive diagnosis.
Differential Diagnosis
Differentiating structural abnormalities of the subarachnoid space from other conditions presenting with similar imaging features is essential for accurate clinical management. Variability in subdural collections, often seen in conditions such as subdural hygroma or chronic subdural hematomas, can complicate the differential diagnosis [PMID:41369522]. The lack of standardized definitions and reference growth curves for eaCSF measurements underscores the need for robust, evidence-based criteria to improve diagnostic accuracy. Conditions like hydrocephalus, where ventricular enlargement is prominent, must also be considered and ruled out through careful imaging analysis. Clinicians should integrate clinical history, including family histories of macrocephaly or neurodevelopmental disorders, alongside imaging findings to narrow down potential diagnoses effectively.
Prognosis & Follow-Up
The prognosis for infants diagnosed with structural abnormalities of the subarachnoid space, particularly those with benign enlargement of the subarachnoid space (BESS), often appears favorable when clinical outcomes are considered. Both reported cases exhibited a benign clinical course, with resolution of subarachnoid space fluid collections by their second year of life [PMID:12653385]. However, these infants maintained head circumferences above the 95th percentile, indicating that while fluid accumulation may normalize, head growth patterns may persist as a long-term characteristic. Regular follow-up MRI scans are crucial to monitor for any recurrence or progression of fluid accumulation and to assess ongoing neurodevelopmental milestones. Clinicians should tailor follow-up intervals based on individual patient trajectories, ensuring timely intervention if developmental concerns arise or if there are signs of clinical deterioration.
Management
Management strategies for structural abnormalities of the subarachnoid space are primarily observational, focusing on close monitoring and supportive care rather than immediate therapeutic intervention. Given the benign course observed in many cases, such as those with BESS, the primary approach involves regular clinical and neuroimaging follow-ups to track any changes in fluid volumes and neurodevelopmental status [PMID:12653385]. In cases where rapid head growth or significant clinical symptoms are present, further investigations into underlying causes, such as genetic predispositions or metabolic disorders, may be warranted. Supportive therapies, including developmental interventions and psychological support for families, can be beneficial, especially in contexts where neurodevelopmental concerns are noted. The decision to pursue more aggressive interventions, such as CSF diversion procedures, should be made cautiously and based on evidence of progressive neurological deficits or complications.
Special Populations
Special attention is warranted for populations with known risk factors, such as those with familial histories of macrocephaly or neurodevelopmental disorders. The reported cases often highlight a potential genetic or familial predisposition to structural abnormalities of the subarachnoid space [PMID:12653385]. Families with a history of macrocephaly should be closely monitored from an early age, given the increased likelihood of similar findings. Genetic counseling may be beneficial to provide families with comprehensive understanding and support regarding potential risks and management strategies. Additionally, infants with siblings or parents affected by neurodevelopmental disorders may require more frequent and detailed assessments to detect early signs of abnormalities and intervene proactively. Tailoring surveillance protocols to these high-risk groups can enhance early detection and management, potentially mitigating long-term neurodevelopmental impacts.
Key Recommendations
These recommendations aim to guide clinicians in effectively managing patients with structural abnormalities of the subarachnoid space, balancing thorough monitoring with supportive care strategies.
References
1 Mandal AS, Dorfschmidt L, Schabdach JM, Gardner M, Yerys BE, Bethlehem RAI et al.. Reference Trajectories of Extra-Axial Cerebrospinal Fluid during Childhood and Adolescence Defined in a Clinically Acquired MRI Dataset. Radiology. Artificial intelligence 2026. link 2 Suara RO, Trouth AJ, Collins M. Benign subarachnoid space enlargement of infancy. Journal of the National Medical Association 2001. link
2 papers cited of 3 indexed.